Ledipasvir is a direct-acting antiviral agent used to treat specific hepatitis C virus (HCV) infections in combination with other antiviral agents. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients.
- Mechanism
- Curator reviewed
Ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) NS5A protein required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required for viral production.
- Primary indication
- When used in combination with the antiviral medication sofosbuvir, ledipasvir is indicated for the treatment of treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with...Curator reviewed · 13 structured indications
- Formula / weight
- C49H54F2N8O6 · 888.9999 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2014 · European Union, 2016
- Code names
- GS-5885 · WHO 9796
- Brand names
Resolves to
VRTWBAAJJOHBQU-KMWAZVGDSA-NSMILESCOC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC=C2NC(=NC2=C1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Ledipasvir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account